# A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus

> **NCT05816057** · PHASE3 · COMPLETED · sponsor: **Hangzhou Jiuyuan Gene Engineering Co. Ltd.,** · enrollment: 476 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **BIOLOGICAL:** semaglutide injection

## Key facts

- **NCT ID:** NCT05816057
- **Lead sponsor:** Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-25
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-10-31
- **Target enrollment:** 476 (ACTUAL)
- **Last updated:** 2024-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05816057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05816057, "A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05816057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*